Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfected patients

Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfected patients Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfected patients Marija Zeremski and Andrew H. Talal Purpose of review Introduction Studies of hepatitis C virus and HIV kinetics during Hepatitis C virus (HCV) is the most common blood- treatment have been instrumental in elucidating the viral borne pathogen that infects approximately 120 million lifecycle and mechanisms of action of antiviral therapies. individuals worldwide and nearly 4 million individuals We sought to review data on hepatitis C virus kinetics in in the United States. HCV coinfection occurs in at least hepatitis C virus/HIV coinfected patients and to illustrate 30% of HIV-infected patients, affecting approximately how viral kinetics might direct therapeutic decisions in these 300 000 individuals in the United States. The majority of patients. coinfected patients develop chronic liver disease that can Recent findings progress to cirrhosis or hepatocellular carcinoma [1 – 3]. Few studies have so far analysed the dynamic changes in Moreover, with the development of effective antiretro- hepatitis C virus RNA after treatment initiation in hepatitis C viral therapy (ART), HCV-induced chronic liver disease virus/HIV coinfected patients. These studies applied has become a leading cause of morbidity and mortality mathematical models previously developed in hepatitis http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfected patients

Talal, Andrew H
Current Opinion in HIV and Aids , Volume 2 (6) – Nov 1, 2007
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/hepatitis-c-viral-kinetics-during-treatment-of-hepatitis-c-virus-hiv-kKrS5Tis8P

References (73)

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e3282f0dcf9
pmid
19372932
Publisher site
See Article on Publisher Site

Abstract

Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfected patients Marija Zeremski and Andrew H. Talal Purpose of review Introduction Studies of hepatitis C virus and HIV kinetics during Hepatitis C virus (HCV) is the most common blood- treatment have been instrumental in elucidating the viral borne pathogen that infects approximately 120 million lifecycle and mechanisms of action of antiviral therapies. individuals worldwide and nearly 4 million individuals We sought to review data on hepatitis C virus kinetics in in the United States. HCV coinfection occurs in at least hepatitis C virus/HIV coinfected patients and to illustrate 30% of HIV-infected patients, affecting approximately how viral kinetics might direct therapeutic decisions in these 300 000 individuals in the United States. The majority of patients. coinfected patients develop chronic liver disease that can Recent findings progress to cirrhosis or hepatocellular carcinoma [1 – 3]. Few studies have so far analysed the dynamic changes in Moreover, with the development of effective antiretro- hepatitis C virus RNA after treatment initiation in hepatitis C viral therapy (ART), HCV-induced chronic liver disease virus/HIV coinfected patients. These studies applied has become a leading cause of morbidity and mortality mathematical models previously developed in hepatitis

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Nov 1, 2007

There are no references for this article.